AzTrials
AzTrials

Ulcerative ColitisPhase 2SHARCNCT06420492

Study of Novel Therapeutics for Acute Remedy of Colitis

A Phase 2 study testing BRS201 in people with Ulcerative Colitis and Ulcerative Colitis Chronic Moderate, run by Brigham and Women's Hospital at 2 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with acute ulcerative colitis. Patients who qualify are adults who have not responded to treatments for their severe ulcerative colitis. Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
BRS201
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
2 sitesUnited States
Study dates
30 Sep 2025to 1 Jun 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Severe outpatient or hospitalized for an acute UC flare
  • Ability to give consent
  • Patients with a confirmed diagnosis of UC for > 3 months
  • History of ≥ 15 cm of colonic involvement as confirmed by colonoscopy
  • Patients with primary sclerosing cholangitis are eligible to enroll
  • Patients will have failed 5 days of oral prednisone 30 mg or greater for 5 days and still having a SCCAI of > 6
Show all 12Show fewer
  • Patients who are taking 20mg or less of oral prednisone and plan to stay at that dose during their participation in the study
  • Accepted medications:
  • Anti-TNF agents are permissible if the patient has been taking them for at least 10 weeks and anticipates to maintain a steady for the duration of the study.
  • Rinvoq (Upadacitinib) is permissible if the subject has been taking this medication for at least 4 weeks and anticipates to maintain a steady dose for the duration of the study.
  • Xeljanz (Tofacitinib) is permissible if the subject has been taking this medication for at least 4 weeks and anticipates to maintain a steady dose for the duration of the study.
  • Other biologics are permissible if the subject has been taking the medication for at least 10 weeks and anticipates to maintain a steady dose for the duration of the study

Who cannot join

  • History of uncontrolled hypertension with systolic BP > 140 and systolic BP > 90
  • Chronic kidney disease as defined by GFR <55mL/min
  • Impaired hepatic function (transaminases elevated > 2.5 x ULN) unless due to PSC
  • Evidence of C. difficile (Negative test result within 1 month is acceptable)
  • Infectious Colitis or drug induced colitis
  • Crohn's Disease or Indeterminate colitis
Show all 17Show fewer
  • Decompensated liver disease
  • Patients who are pregnant or breastfeeding
  • Patients who have a confirmed malignancy or cancer within 5 years
  • Congenital or acquired immunodeficiencies
  • Other comorbidities including: Diabetes mellitus, systemic lupus
  • Participation in a therapeutic clinical trial in the preceding 30 days or simultaneously during this trial
  • Patients with a history or risk of cardiovascular conditions, including arrhythmia, long QT syndrome, congestive heart failure, stroke, or coronary artery disease
  • Prohibited medications:
  • Rinvoq (Upadacitinib): Subjects will be excluded from this study if their last dose of this medication was administered within 4 weeks. If subjects have stopped taking this medication and their last dose was administered more than 4 weeks prior to enrollment, they will be eligible for participation.
  • Xeljanz (Tofacitinib): Subjects will be excluded from this study if their last dose of this medication was administered within 4 weeks. If subjects have stopped taking this medication and their last dose was administered more than 4 weeks prior to enrollment, they will be eligible for participation.
  • Other Medications: Subjects will be excluded from this study if they stopped taking any other medications for ulcerative colitis within 8 weeks. If subjects have stopped taking the medication and their last dose was more than 8 weeks prior to enrollment, they will be eligible for participation.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Joshua Korzenik, MD contact

617 732-6389

jkorzenik@bwh.harvard.edu

Siani Ellis contact

617-396-7703

sellis13@bwh.harvard.edu

United States2 sites, 2 recruiting

  • Brigham and Women's Hospital

    Chestnut Hill, Massachusetts, 02467

    Siani Ellis, 617-396-7703, sellis13@bwh.harvard.edu

    Sophie Mitchell, smitchell22@bwh.harvard.edu

    Not yet recruiting

  • Brigham and Women's Hospital

    Chestnut Hill, Massachusetts, 02467

    Siani Ellis, 617-396-7703, sellis13@bwh.harvard.edu

    Recruiting

Other trials in United States

About this study

This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with acute ulcerative colitis. Patients who qualify are adults who have not responded to treatments for their severe ulcerative colitis. Participation in this study will take 12 weeks long and the study is structured as an open-label pilot study in which participants will take the study drug for 4 weeks in the form of an oral medication. Participation may also involve receiving an IV dose of the medication. The study will require participants to attend 8 study visits, all of which will be conducted at a study site. Participation will involve taking an oral medication twice daily, tracking the medication in a log, and getting blood drawn and giving a stool and urine sample for a few lab tests throughout the study. Participants may also undergo a flexible sigmoidoscopy at the beginning and end of the study.

Being tested
BRS201
Medical subject headings
Colitis, Ulcerative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BRS201Drug

    Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug for four weeks.

Study groups in NCT06420492
Study groupRoleWhat they receive
BRS201 ArmExperimentalIn Group 1 of the study, subjects will take oral study drug at 1.2g daily, PO with 120mg oral butyrate twice daily (240mg daily) for 4 weeks. In Group 3 of the study, subjects will take oral study drug at 1.2g twice daily, PO (2.4g daily) with 120mg oral butyrate twice daily (240mg daily) for 4 weeks. In Group 3 of the study, subjects will take oral study drug at 1.2g twice daily, PO (2.4g daily) with 120mg oral butyrate twice daily (240mg daily) for 4 weeks. Subjects will also receive a one time 2.5g dose of study drug at initiation. In Group 4 of the study, subjects will repeat the previous conditions of the group that proves to be the most effective. Subjects in Group 4 will undergo two flexible sigmoidoscopies, one at screening and one at week 4.
Receives: Drug: BRS201

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sulfur Metabolism

    The primary measure of dose response will be urinary measures of sulfur metabolism including a > 50% reduction from pretreatment levels sulfate, and thiosulfate.

    Measured: 4 weeks

Secondary outcomes (8)

  1. Simple Clinical Colitis Activity Index (SCCAI)

    Clinical symptoms assessed by SCCAI which measures patient reported outcomes on a scale of 0 to 19, where a higher score indicates more severe activity and active disease is a score of 5 or more.

    Measured: 12 weeks

  2. Plasma nitrite, nitrate, or nitrosothiol

    Correlation between changes in plasma nitrite, nitrate or nitrosothiol level in relation to calprotectin

    Measured: 8 weeks

  3. Normalization of fecal calprotectin lab measurements

    The capacity of study drug to normalize fecal calprotectin levels from baseline (week 0) compared to end of active treatment (4 weeks) and at week 6.

    Measured: 8 weeks

  4. Reduction in fecal calprotectin lab measurements

    Reduction in fecal calprotectin to < ULN at the end of active treatment

    Measured: 4 weeks

  5. Mayo Score

    The primary endpoint for this study is change in Total Mayo Score with improvement being a reduction in 3 points and remission being a score of 0 or 1 from day 0 to end of week 4 (at second flexible sigmoidoscopy).

    Measured: 4 weeks

  6. Tissue Analysis

    Analysis of tissue metabolomics and proteomics at day 0 vs day 28;

    Measured: 4 weeks

  7. Mitochondria evaluation

    Changes in mitochondria on EM evaluation

    Measured: 12 weeks

  8. Urine Assays

    Urine levels for thiosulfate, thiocyanate, nitrate and nitrite;

    Measured: 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 May 2024
  2. Study start30 Sep 2025
  3. Primary completion1 Dec 2026 (estimated)
  4. Study completion1 Jun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
This is an open-label study in which everyone will receive active treatment.
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06420492
Sponsor's protocol ID
2025P001885
Acronym
SHARC
Status last verified
Oct 2025
First submitted
6 May 2024
Last updated
20 Oct 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing BRS201 in people with Ulcerative Colitis and Ulcerative Colitis Chronic Moderate, run by Brigham and Women's Hospital at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 20 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Joshua Korzenik, MD (617 732-6389, jkorzenik@bwh.harvard.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sulfur Metabolism (time frame: 4 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06420492.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in